Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GP8N
|
|||
| Former ID |
DNCL002353
|
|||
| Drug Name |
MK-8808
|
|||
| Indication | Follicular lymphoma [ICD-11: 2A80; ICD-10: C81-C86, C82] | Phase 3 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20] | Phase 1 | [1] | ||
| Company |
Merck
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | Agonist | [2] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034367) | |||
| REF 2 | Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003 Oct 20;22(47):7359-68. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.